echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Prospects of drug patent links: Who will be the first person to eat crabs?

    Prospects of drug patent links: Who will be the first person to eat crabs?

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Author | kevindy

    The patent linkage system originated in the "Hatch-Waxman Act" of 1984 in the United States, aiming to balance the interests of innovative drug companies and generic drug companies
    .

    China’s drug patent linkage system has been implemented for more than one month.
    Can this system design, which aims to promote healthy competition between generic drug companies and original research drug companies, really promote domestic drug research and development? Who will become the first company to challenge patents after the implementation of this system? How about a successful company becoming the first to eat crabs?

    Patent linkage system

    Patent linkage system

    The patent linkage system originated in the "Hatch-Waxman Act" of 1984 in the United States, aiming to balance the interests of innovative drug companies and generic drug companies
    .


    The so-called patent link refers to the "link" of the generic drug that is applied for on the market with the patent of the original research drug it imitates


    Article 11 of the "Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes (Trial)" stipulates that "the first chemical generic drug that successfully challenged the patent and was approved for marketing shall be granted a period of market exclusivity
    .


    The same kind of generic drugs will not be approved for marketing within 12 months from the date of approval, except for the successful joint challenge of patents


    Crab Eater

    Crab Eater

    As of August 6, 2021, a total of 89 patent declarations of generic drug companies have been queried on the Chinese listed drug patent information registration platform, including 87 chemical drugs, 2 biological products, and no Chinese medicines
    .


    The statistics of the types of patent declarations are shown in Figure 1.


    Distribution of number of patent declarations

    Jiangsuhausen

    Jiangsuhausen

    The first company to declare to challenge the patent was Jiangsu Hausen, and the declared product was dapagliflozin
    .


    The patent layouts of the original research manufacturers of this variety are compound patents, crystal form patents and preparation patents, and their patent protection periods are 2023, 2027, and 2028, respectively


    Source: China listed drug patent information registration platform

    Biopharmaceuticals

    Biopharmaceuticals

    The second pharmaceutical company to challenge the patent was Beijing Biopharma.
    The declared product was an ibuprofen suspension, and it was also a generic drug company to challenge
    .


    However, judging from the drug number of the ibuprofen suspension approved by the patent enterprise and the registered patent protection content, the registered patent protects the compound preparation of Chinese and Western medicine made of ibuprofen and Chinese medicine ingredients.


    Source: China listed drug patent information registration platform

    Huahai Pharmaceutical

    Huahai Pharmaceutical

    The third pharmaceutical company that raised a patent challenge was Huahai Pharmaceutical, and the declared product was lurasidone hydrochloride tablets
    .


    The two patents of the original manufacturer of the product are both pharmaceutical composition patents and belong to the relationship between the original case and the divisional case.


    Source: China listed drug patent information registration platform

    With the implementation of this system, it is believed that more and more pharmaceutical companies will challenge patents, and more and more pharmaceutical companies will successfully challenge patents
    .


    Compared with the success of challenging patents, I think we need to pay more attention to the implementation of favorable measures after the success of subsequent challenges


    We will wait and see who will be the first person to eat crabs!

    references:

    "Implementation Measures for Early Resolution Mechanisms for Drug Patent Disputes (Trial)"

    "Quick Look! In-depth interpretation of China's patent linkage system! 》

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.